Low Co-Pays Drive Better Adherence to New Diabetes Drugs at HealthBulance.

Health care is our expertise. The less US patients pay out of pocket for drugs that often have high co-pays, such as sodium-glucose cotransporter 2 (SGLT2) inhibitors or glucagon-like peptide-1 (GLP-1) agonists, the more adherent they are.

Medscape

Low Co-Pays Drive Better Adherence to New Diabetes Drugs

Low Co-Pays Drive Better Adherence to New Diabetes Drugs

The less US patients pay out of pocket for drugs that often have high co-pays, such as sodium-glucose cotransporter 2 (SGLT2) inhibitors or glucagon-like peptide-1 (GLP-1) agonists, the more adherent they are.